ABN Amro Investment Solutions Has $1.87 Million Position in Natera, Inc. $NTRA

ABN Amro Investment Solutions grew its position in shares of Natera, Inc. (NASDAQ:NTRA) by 44.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,346 shares of the medical research company’s stock after buying an additional 2,883 shares during the quarter. ABN Amro Investment Solutions’ holdings in Natera were worth $1,869,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Natera by 10.5% in the 4th quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock valued at $2,944,800,000 after buying an additional 1,225,420 shares during the period. Wellington Management Group LLP grew its position in shares of Natera by 94.7% in the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares during the period. State Street Corp raised its stake in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the period. Coatue Management LLC lifted its position in Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock worth $603,270,000 after buying an additional 2,463,008 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Natera by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 2,608,644 shares of the medical research company’s stock worth $596,078,000 after acquiring an additional 11,689 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently weighed in on NTRA. Guggenheim boosted their target price on Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, June 29th. The Goldman Sachs Group began coverage on shares of Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 target price for the company. Wolfe Research began coverage on shares of Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price for the company. Robert W. Baird set a $265.00 price target on shares of Natera in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. upped their target price on Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Insider Buying and Selling at Natera

In related news, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the sale, the director directly owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Herm Rosenman sold 16,530 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 178,872 shares of company stock worth $39,627,696 in the last quarter. Company insiders own 5.05% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $261.99 on Friday. The firm’s fifty day moving average is $240.75 and its 200-day moving average is $221.61. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $288.04. The firm has a market cap of $37.52 billion, a PE ratio of -160.73 and a beta of 1.51.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.